| Patents for G01N 33 - Investigating or analysing materials by specific methods not covered by groups (393,632) |
|---|
| 06/07/2011 | CA2576930C Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein |
| 06/07/2011 | CA2493743C A method to quantitatively analyze conjugated dienes in hydrocarbon feeds and products as an indicator of fouling potential |
| 06/07/2011 | CA2490467C Method for detecting and for removing endotoxin |
| 06/07/2011 | CA2442604C Systems and methods for automated analysis of cells and tissues |
| 06/07/2011 | CA2441436C Methods and kits for determing a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer |
| 06/07/2011 | CA2418422C Novel kallikrein gene |
| 06/07/2011 | CA2414433C System with a pluggable data transfer module which transfers data from an analytical system to a data processing unit |
| 06/07/2011 | CA2407973C Biological identification system with integrated sensor chip |
| 06/07/2011 | CA2404431C Guanylyl cyclase c in the detection of stomach and esophageal cancers |
| 06/07/2011 | CA2400993C Carriers coated with polysaccharides, their preparation and use |
| 06/07/2011 | CA2378866C Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| 06/07/2011 | CA2305774C Testing device for determining analytes in a liquid dairy product |
| 06/07/2011 | CA2289972C Screening assays for agents that alter inhibitor of apoptosis (iap) protein regulation of caspase activity |
| 06/07/2011 | CA2230556C Novel procollagens |
| 06/07/2011 | CA2165949C Tuberculosis vaccine |
| 06/03/2011 | WO2011066583A1 Amyloid beta aggregates in cerebro spinal fluid as biomarkers for alzheimer's disease |
| 06/03/2011 | WO2011066527A1 Zinc status biomarker materials and related methods |
| 06/03/2011 | WO2011066521A2 Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
| 06/03/2011 | WO2011066504A1 Methods and compositions for detecting methicillin-resistant staphylococcus aureus |
| 06/03/2011 | WO2011066497A2 Methods and apparatus for segregation of particles, including segregation and proliferation of fetal and stem cells |
| 06/03/2011 | WO2011066460A1 Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition |
| 06/03/2011 | WO2011066458A2 Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| 06/03/2011 | WO2011066455A1 Grease test kit and methods of testing grease |
| 06/03/2011 | WO2011066449A1 Devices for detection of analytes |
| 06/03/2011 | WO2011066383A1 Methods and devices for detecting unsaturated compounds |
| 06/03/2011 | WO2011066380A1 Biomarkers for the diagnosis of kidney graft rejection |
| 06/03/2011 | WO2011066372A2 Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity |
| 06/03/2011 | WO2011066351A1 Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
| 06/03/2011 | WO2011066265A1 Cancer testis antigens as biomarkers in non-small cell lung cancer |
| 06/03/2011 | WO2011066258A1 Targeted separation of cultured cells |
| 06/03/2011 | WO2011066221A1 Immunogen prioritization for vaccine design |
| 06/03/2011 | WO2011066185A1 Microfluidic devices and methods for gene synthesis |
| 06/03/2011 | WO2011066132A1 Use of sarcoplasmic ca2+-atpase type 2 protein for diagnosing and treating learning or mental disorders |
| 06/03/2011 | WO2011066101A1 Multi-purpose substrates useful for cell culture and methods for making and using the same |
| 06/03/2011 | WO2011066008A2 Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection |
| 06/03/2011 | WO2011065976A1 Detection of intraamniotic infection |
| 06/03/2011 | WO2011065913A1 Method and system for binding behavior analysis |
| 06/03/2011 | WO2011065912A1 Method and system for interaction analysis |
| 06/03/2011 | WO2011065814A1 Methods and system for recognizing wood species |
| 06/03/2011 | WO2011065762A2 System for measuring, using a qms, an absolute quantity of each component of a gas |
| 06/03/2011 | WO2011065753A2 Flow cytometry method through the control of fluorescence intensities |
| 06/03/2011 | WO2011065751A2 Membrane biosensor to which a porous film is attached, and a method for measuring immune reactions or enzyme reactions employing the same |
| 06/03/2011 | WO2011065747A2 Rapid detection method for microorganisms using nanoparticles |
| 06/03/2011 | WO2011065729A2 Biosensor |
| 06/03/2011 | WO2011065666A2 Centrifugal micro-fluidic device and method for detecting target in fluid sample |
| 06/03/2011 | WO2011065573A1 Homogenous measurement method and measuring reagent |
| 06/03/2011 | WO2011065533A1 Method for determination of sensitivity to pre-operative chemotherapy for breast cancer |
| 06/03/2011 | WO2011065475A1 Method for screening drug efficacious in treating dry eye and/or keratoconjunctival disorders and pharmaceutical composition obtained thereby |
| 06/03/2011 | WO2011065398A1 Optical sensor and manufacturing method therefor |
| 06/03/2011 | WO2011065389A1 Method for screening of therapeutic agent for hyperlipemia |
| 06/03/2011 | WO2011065340A1 Measurement method of degradation/alteration degree of lubricant oil and measurement device thereof |
| 06/03/2011 | WO2011065308A1 Fluorescent probe |
| 06/03/2011 | WO2011065212A1 Method for analyzing biological sample component |
| 06/03/2011 | WO2011065195A1 Microchip and film |
| 06/03/2011 | WO2011065177A1 Blood cell trajectory display device |
| 06/03/2011 | WO2011065176A1 Microchip and blood analysis system |
| 06/03/2011 | WO2011065168A1 Method and apparatus for prediction of pharmacological efficacy of humanized anti-tnfα antibody drug on rheumatoid arthritis |
| 06/03/2011 | WO2011065029A1 Method for screening for adjuvant |
| 06/03/2011 | WO2011064981A1 Immunoassay method |
| 06/03/2011 | WO2011064910A1 Immunity measurement method |
| 06/03/2011 | WO2011064788A1 A method and a kit for detection of acute coronary syndrome based on concentration of unbound iron present in a biological sample |
| 06/03/2011 | WO2011064740A2 Product and preparation process of a substrate for a rapid detection of helicobacter pylori |
| 06/03/2011 | WO2011064595A1 Aquatic polution monitoring |
| 06/03/2011 | WO2011064459A1 Dust collecting and analysing apparatus and method for determining the size and mass of particles detaching from fibrous material |
| 06/03/2011 | WO2011064423A1 Device for collecting, transporting and filtering faecal parasites |
| 06/03/2011 | WO2011064407A1 Agents for treating disease |
| 06/03/2011 | WO2011064358A1 Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction |
| 06/03/2011 | WO2011064351A1 Kinin b1 receptor as a biomarker of airway inflammation related to smoke exposure |
| 06/03/2011 | WO2011064324A1 Method of diagnosis of fibrotic diseases |
| 06/03/2011 | WO2011064310A1 Method and arrangement for gas chromatographic analysis of a gas sample |
| 06/03/2011 | WO2011064308A1 Method for predicting the response of a tumour disease to a therapeutic measure |
| 06/03/2011 | WO2011064225A1 Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment |
| 06/03/2011 | WO2011064179A1 Marker protein for type 2 diabetes |
| 06/03/2011 | WO2011064000A1 Method for monitoring, identifying or diagnosing a bacterial infection |
| 06/03/2011 | WO2011063994A1 A device and a method for measuring fluid-mechanically effective material parameters of a fluid |
| 06/03/2011 | WO2011063470A1 Lipid biomarkers for stable and unstable heart disease |
| 06/03/2011 | WO2011063469A1 Tubulin biomarker assay |
| 06/03/2011 | WO2011063454A1 Method for influencing sex selection ' in artificial insemination and apparatus for same |
| 06/03/2011 | WO2011063453A1 Methods, kits and reagents for diagnosing, aiding diagnosis and/or monitoring progression of a neurological disorder |
| 06/03/2011 | WO2011040884A3 Microfluidic devices with removable cover and methods of fabrication and application |
| 06/03/2011 | WO2011040882A3 Water-soluble silsesquioxanes as organic quantum dots for sensing and imaging |
| 06/03/2011 | WO2011039271A3 Method and assembly for determining cell vitalities |
| 06/03/2011 | WO2011035322A3 Probes and primers for binding, detecting, differentiating, isolating and sequencing of influenza a strains |
| 06/03/2011 | WO2011034620A3 Integrated cartridge |
| 06/03/2011 | WO2011025891A3 Anti-coagulant calibrant infusion fluid source |
| 06/03/2011 | WO2011022438A3 Cleavage sensitive antibodies and methods of use thereof |
| 06/03/2011 | WO2011019807A3 Measurement of mitochondrial membrane potential to assess organ dysfunction |
| 06/03/2011 | WO2011017691A3 Enhanced molecular detection of targeted intracellular mrna transcription using polynucleotide functionalized nanoparticles |
| 06/03/2011 | WO2011017681A3 Device and method for molecular analysis |
| 06/03/2011 | WO2011017436A3 A high precision quantitative assay composition and methods of use therefor |
| 06/03/2011 | WO2011015353A3 Portable handheld medical diagnostic devices |
| 06/03/2011 | WO2011011453A3 Phenotyping tumor-infiltrating leukocytes |
| 06/03/2011 | WO2011008831A3 Mass tags for spectrometric analysis of immunoglobulins |
| 06/03/2011 | WO2010137873A9 Primer for the diagnosis of the new influenza a virus, probe, kit comprising same, and diagnosis method using the kit |
| 06/03/2011 | WO2010100381A9 Novel antiviral agent |
| 06/03/2011 | CA2782266A1 Anticancer compounds and screening method |
| 06/03/2011 | CA2782211A1 Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection |
| 06/03/2011 | CA2782176A1 Methods and apparatus for segregation of particles, including segregation and proliferation of fetal and stem cells |
| 06/03/2011 | CA2782045A1 Dyes for analysis of protein aggregation |
| 06/03/2011 | CA2781952A1 Amyloid beta aggregates in cerebro spinal fluid as biomarkers for alzheimer's disease |